Literature DB >> 21062615

Antidepressants and body weight: a comprehensive review and meta-analysis.

Alessandro Serretti1, Laura Mandelli.   

Abstract

OBJECTIVE: Psychotropic drugs often induce weight gain, leading to discomfort and discontinuation of treatment and, more importantly, increasing the risk of obesity-related illnesses such as diabetes mellitus, hypertension, and coronary heart disease. There is evidence that antidepressant drugs may induce a variable amount of weight gain, but results are sparse and often contradictory. DATA SOURCES: We performed a literature search using the MEDLINE, ISI Web of Knowledge, and Cochrane research databases for all publications available to January 2009. We used the following keywords: antidepressant, psychotropic drugs, body weight, weight gain, obesity, overweight, adverse event, side effects, SSRIs, tricyclic antidepressants, and the name of each antidepressant active compound together with body weight or other keywords. Studies reporting body weight changes during treatment with different antidepressants were selected for eligibility. Finally, 116 studies were included in the analysis. DATA EXTRACTION: Weight change mean and standard deviation and size of each group were recorded. Missing means and standard deviations were directly calculated by using information available in the article when possible. Non-placebo-controlled studies were compared to a virtual placebo sample, whose mean and standard deviation were derived by the weighted mean of means and standard deviations of all placebo samples. Methodological quality of studies, heterogeneity, publication bias, and effect of treatment duration were systematically controlled. DATA SYNTHESIS: Quantitative results evidenced that amitriptyline, mirtazapine, and paroxetine were associated with a greater risk of weight gain. In contrast, some weight loss occurs with fluoxetine and bupropion, although the effect of fluoxetine appears to be limited to the acute phase of treatment. Other compounds have no transient or negligible effect on body weight in the short term. However, the effect of each antidepressant may vary greatly depending on an individual's characteristics and generally became more evident in the long term to a variable degree across compounds.
CONCLUSIONS: Despite the fact that some analyses were done on only a few studies due to the difficulty of finding reliable information in literature, to our knowledge, this is the first comprehensive meta-analysis to allow comparison of different antidepressants as regards their impact on body weight. Data presented may be helpful for a more accurate treatment selection in patients at risk of obesity or related medical illness. © Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062615     DOI: 10.4088/JCP.09r05346blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  145 in total

1.  The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors.

Authors:  Giselle G Hamad; Joseph C Helsel; James M Perel; Gina M Kozak; Mary C McShea; Carolyn Hughes; Andrea L Confer; Dorothy K Sit; Carol A McCloskey; Katherine L Wisner
Journal:  Am J Psychiatry       Date:  2012-03       Impact factor: 18.112

Review 2.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

3.  Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.

Authors:  Lauren D Garfield; David Dixon; Petra Nowotny; Francis E Lotrich; Bruce G Pollock; Sean D Kristjansson; Peter M Doré; Eric J Lenze
Journal:  Am J Geriatr Psychiatry       Date:  2013-09-08       Impact factor: 4.105

4.  The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.

Authors:  Brandon Mansoor; Manivel Rengasamy; Robert Hilton; Giovanna Porta; Jiayan He; Anthony Spirito; Graham J Emslie; Taryn L Mayes; Gregory Clarke; Karen Dineen Wagner; Wael Shamseddeen; Boris Birmaher; Neal Ryan; David Brent
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-11       Impact factor: 2.576

Review 5.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

6.  Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase®.

Authors:  Thi Thu Ha Nguyen; Anne Roussin; Vanessa Rousseau; Jean-Louis Montastruc; François Montastruc
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

7.  Bupropion in the treatment of major depressive disorder in real-life practice.

Authors:  Diogo Azevedo Oliveira Sennfelt; Maria Alice Rodrigues Marques da Silva; Anabela Pereira da Silva Tavares
Journal:  Clin Drug Investig       Date:  2011-10-19       Impact factor: 2.859

8.  Diet-induced changes in the Lean Brain: Hypercaloric high-fat-high-sugar snacking decreases serotonin transporters in the human hypothalamic region.

Authors:  Karin Eva Koopman; Jan Booij; Eric Fliers; Mireille Johanna Serlie; Susanne Eva la Fleur
Journal:  Mol Metab       Date:  2013-08-07       Impact factor: 7.422

9.  A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.

Authors:  H Suplicy; C L Boguszewski; C M C dos Santos; M do Desterro de Figueiredo; D R Cunha; R Radominski
Journal:  Int J Obes (Lond)       Date:  2013-11-29       Impact factor: 5.095

10.  Fluoxetine augments ventilatory CO2 sensitivity in Brown Norway but not Sprague Dawley rats.

Authors:  Matthew R Hodges; Ashley E Echert; Madeleine M Puissant; Gary C Mouradian
Journal:  Respir Physiol Neurobiol       Date:  2013-02-27       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.